Innovative Eyewear Inc.

Innovative Eyewear, Inc. (Nasdaq: LUCY; LUCYW) announced in its Q3 business update that it has surpassed $1 million in quarterly revenue for the first time, marking twelve consecutive quarters of year-over-year growth. The company also revealed a strategic alliance with HTC to introduce the VIVE Eagle camera glasses to the U.S. market, and its upcoming big box store test has tripled in size, with a 375-store rollout at Canada's FYiDoctors beginning in September. Operating expenses have fallen from 467% of revenue in Q1 2025 to 193% in Q2 2026, and net loss narrowed from 391% to 165% over the same period. Lucyd Armor is undergoing commercial tests with DHL, ExxonMobil, ThermoKing, ABM Inc., and Fastenal, and the company is partnering with Qualcomm on an improved chipset. Upcoming launches include the HTC VIVE Eagle in mid-September and Lucyd Aero in mid-October.

Innovative Eyewear shares surged 63% after the company reported preliminary second-quarter net sales of approximately $0.99 million, a 71% year-over-year increase, and announced new retail partnerships in Canada and the United States. The company received an initial purchase order from a Canadian optical retail group with 345 locations and was awarded a 50-store test with a major U.S. retailer, both expected to begin in the third quarter of 2026. Separately, Seer jumped 35% after its Chair and CEO proposed to acquire all outstanding Class A shares for $2.45 per share in cash plus two contingent value rights, with the board forming a special committee to evaluate the offer. Orthofix and Enovis rallied over 15% each after CMS withdrew reimbursement changes for non-invasive bone growth stimulators, restoring Medicare rates to pre-May 2026 levels. Other notable movers included YD Bio, up 23% on no specific news, and Adlai Nortye, which gained 15% amid progress updates on its cancer therapy pipeline.